Integrated BioPharma Reports Results for its Quarter Ended September 30, 2019

ACCESSWIRE
14 Nov 2019, 06:43 GMT+10

HILLSIDE, NJ / ACCESSWIRE / November 13, 2019 / Integrated BioPharma, Inc. (OTC BB:INBP) (the 'Company') reports it financial results for the quarter ended September 30, 2019.

Revenue for the quarter ended September 30, 2019 was $11.4 million compared to $10.3 million for the quarter ended September 30, 2018, an increase of $1.1 million or 10.7%. The Company had operating income for the quarter ended September 30, 2019 of $0.5 million compared to operating income of $0.4 million for the quarter ended September 30, 2018.

For the quarter ended September 30, 2019, the Company had net income and diluted net income of $0.3 million or $0.01 per share of common stock, compared with net income and diluted net income of $0.2 million or $0.01 per share of common stock for the quarter ended September 30, 2018.

'We are excited to report that our revenue increased by approximately 11% in the quarter ended September 30, 2019 and that our revenue from our two significant customers in our Contract Manufacturing Segment remained consistent; representing approximately 91% and 89% of total revenue in the quarters ended September 30, 2019 and 2018, respectively,' said Riva Sheppard, Co-Chief Executive Officer of the Company.

A summary of our financial results for the three months ended September 30, 2019 follows:

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
(unaudited)
	Three Months Ended
	September 30,
	2019			2018

Total revenue	$	11,406		$	10,304
Cost of sales		10,007			9,085
Gross profit		1,399			1,219
Selling and administrative expenses		923			814
Operating income		476			405
Other expense, net ⁽¹⁾		(127	)		(191	)

Income before income taxes		349			214
Income tax expense, net		37			55
Net income	$	312		$	159

Net income per common share:
Basic	$	0.01		$	0.01
Diluted	$	0.01		$	0.01
Weighted average common shares outstanding:
Basic		29,565,943			27,218,786
Diluted		30,724,633			27,963,604



⁽¹⁾ Includes interest expense of $124 and $200, respectively.

SOURCE: Integrated BioPharma, Inc.

View source version on accesswire.com:
https://www.accesswire.com/566451/Integrated-BioPharma-Reports-Results-for-its-Quarter-Ended-September-30-2019

Watch latest videos

News RELEASES

Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Miami Mirror.

More Information

83 ℉

Fair in Miami

Business

Section

Hong Kong stocks appreciate, elsewhere markets slide

NEW YORK, New York - Stocks in Asia were mostly on Wednesday, in line with the sell-off globally a day ...

U.S. stocks waver after strong rally of recent days

NEW YORK, New York - Uncertainty over the future predominance of the coronavirus disease Covid-19 gave Wall Street a panic ...

Vouchers instead of refunds in case of canceled flights disappoint

Despite unrelenting pressures from passenger rights advocates, intense media scrutiny and strident demands from passengers, airlines have remained largely immutable ...